For immediate release |
5 June 2008 |
Advanced Medical Solutions Group plc
('AMS' or 'the Company')
Directors' shareholdings
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that the following Directors purchased ordinary shares of 5 pence each ('Ordinary Shares') on 4 June 2008, as part of the Deferred Share Bonus Plan. These Ordinary Shares were bought at a price of 33.5p per share and, under the terms of the Plan, will be held in trust on their behalf.
Name of Director |
Shares purchased |
Resultant holding |
% of issued share capital |
Don Evans |
29,850 |
793,702 |
0.55 |
Mary Tavener |
28,357 |
183,778 |
0.13 |
Chris Meredith |
19,402 |
74,402 |
0.05 |
AMS also announces the following share purchase of Ordinary Shares by the Chairman, Geoffrey Vernon, on 4 June 2008, at a price of 33.5p per share. These shares will not be part of the Deferred Share Bonus Plan.
Name of Director |
Shares purchased |
Resultant holding |
% of company held |
Geoffrey Vernon |
40,000 |
1,000,000 |
0.69 |
The Company also announced that application has been made to the London Stock Exchange for the admission of 13,432 Ordinary Shares. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue. It is expected that admission will become effective on 8th June 2008.
For further information, please contact:
Advanced Medical Solutions Group plc |
|
Don Evans, Chief Executive Officer Mary Tavener, Finance Director |
Tel: +44 (0) 1606 545508 |
|
|
Buchanan Communications |
Tel: +44 (0) 20 7466 5000 |
Mark Court, Mary-Jane Johnson Landsbanki Securities (UK) Ltd Shaun Dobson, Claes Spang |
Tel: +44 (0) 20 7426 9000 |
Notes to Editors:
Advanced Medical Solutions is a leading company in the development, manufacture and sale of products into the $15 billion global woundcare market.
Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.
In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS' resources ensure a unique position as a vertically integrated 'one stop shop' to provide all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery ready for distribution into customer markets.
AMS' technology in cyanoacrylate based tissue adhesives is used either for the closure of small cuts and trauma wounds through to large surgical incisions, or for protecting or sealing skin to prevent breakdown or infection.
AMS' products currently serve the majority of the key global markets sold either direct or through strategic partners or distributors.